The company has an early stage pipeline of novel, multi-cistronic gene therapy products targeting diabetic macular edema (DME), age-related macular degeneration (AMD, both wet and dry forms) and ocular hypertension.
Location: United Kingdom
Employees: 1-10
Total raised: $13.32M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 14.09.2021 | Future Pla... | futureplan... |
| - | Life Arc V... | lifearcven... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.12.2024 | - | $10.07M | - |
| 05.02.2020 | Seed | $3.25M | - |
Mentions in press and media 5
| Date | Title | Description |
| 06.01.2026 | Ikarovec to Advance Pipeline With Exclusive Worldwide Option to VectorBuilder’s Intravitreal Capsid Technology | Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive worldwide option agreement for VectorBui... |
| 30.12.2024 | Ikarovec – seed funding round closes at £8m | We are delighted to announce our investment in Ikarovec as part of their seed funding round. Ikarovec is a biotech gene therapy company with a focus on ophthalmology. Norwich, UK, October 2024 – Ikarovec, which is developing novel bicistron... |
| 05.02.2020 | Ophthalmic gene therapy company Ikarovec launches with £2.5m seed funding | Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has launched today with £2.5m of seed funding from leading UK start-up investors UKI2S, LifeArc and Parkwalk. Primary use of funds is to take the comp... |
| 05.02.2020 | Ikarovec Raises £2.5M in Seed Funding | Ikarovec, a Cambridge, UK-based ophthalmic gene therapy company, raised £2.5m in seed funding. Backers included investors UKI2S, LifeArc and Parkwalk. In conjunction with the funding, Oliver Sexton, Investment Director at UKI2S, David Holbr... |
| 05.02.2020 | Ophthalmic gene therapy company Ikarovec launches with £2.5m seed funding | Ophthalmic gene therapy company Ikarovec launches with £2.5m seed funding 05-02-2020 Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has launched today with £2.5m of seed funding from leading UK sta... |